Clinical Report: Personalizing Steroid Duration in Asthma

Overview

A randomized controlled trial demonstrated that an eosinophil-guided approach to systemic corticosteroid duration is noninferior to standard care in hospitalized asthma patients, while reducing cumulative steroid exposure for those with noneosinophilic exacerbations. Treatment failure rates were comparable between the two strategies.

Background

Asthma exacerbations often require systemic corticosteroids, traditionally administered for fixed durations. However, this approach may lead to unnecessary steroid exposure, which can have cumulative adverse effects. Personalizing corticosteroid duration based on baseline blood eosinophil counts could optimize treatment and minimize risks.

Data Highlights

Key Findings

• 60% of participants had eosinophilic exacerbations; 40% were noneosinophilic.
• No significant differences in overall cumulative systemic corticosteroid exposure between groups.
• Within the eosinophil-guided group, noneosinophilic patients received lower cumulative doses.
• Hospital length of stay and secondary outcomes were similar across both groups.
• Low rates of pneumonia and corticosteroid-associated adverse events were observed.

Clinical Implications

Clinicians may consider utilizing baseline blood eosinophil counts to tailor corticosteroid therapy duration in hospitalized asthma patients, particularly for those with noneosinophilic exacerbations. This approach could reduce unnecessary steroid exposure without compromising patient safety.

Conclusion

The eosinophil-guided strategy for corticosteroid duration in asthma exacerbations is a promising alternative to standard care, offering a balance between effective treatment and reduced steroid exposure.

References

1. Yii A, et al., Thorax, 2025 -- Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial
2. GINA, 2024 -- 2024 changes to GINA Strategy Report: archive copy
3. Drug Safety — Evaluation of the Safety Profile of On-Demand Budesonide-Formoterol in Mild Asthma: Insights from the Phase III SYGMA Trials
4. Drugs - Real World Outcomes — Evaluating the Risk of Severe COPD Exacerbations and Long-Acting Bronchodilator Therapies: A Comparison of Three Observational Data Analysis Approaches
5. Intensive Care Medicine — Discussion on the study "Impact of Hydrocortisone on Mortality Rates in Severe Community-Acquired Pneumonia Patients: Findings from the REMAP-CAP Corticosteroid Domain Randomized Clinical Trial
6. The New Gastroenterologist — Long-Term Findings Endorse Reduced-Dose Maintenance Therapy for Eosinophilic Esophagitis
7. Evaluation of the Safety Profile of On-Demand Budesonide-Formoterol in Mild Asthma: Insights from the Phase III SYGMA Trials
8. Evaluating the Risk of Severe COPD Exacerbations and Long-Acting Bronchodilator Therapies: A Comparison of Three Observational Data Analysis Approaches
9. 2024 changes to GINA Strategy Report: archive copy
10. https://www.progettolibra.it/ljc/LIBRA_JOURNAL_CLUB_3-8_DEC_2025.pdf
11. Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial | Thorax